Antivirals for influenza-like illness? a randomised controlled trial of clinical and cost effectiveness in primary carE (ALIC4 E): the ALIC4 E protocol

Simple item page
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia, e Pediatríagl
dc.contributor.authorBongard, Emily
dc.contributor.authorVan der Velden, Alike W.
dc.contributor.authorCook, Johanna
dc.contributor.authorSaville, Ben
dc.contributor.authorBeutels, Philippe
dc.contributor.authorAabenhus, Rune Munck
dc.contributor.authorBrugman, Curt
dc.contributor.authorChlabicz, Slawomir
dc.contributor.authorCoenen, Samuel
dc.contributor.authorColliers, Annelies
dc.contributor.authorDavies, Melanie
dc.contributor.authorDe Paor, Muireann
dc.contributor.authorDe Sutter, An
dc.contributor.authorFrancis, Nick A.
dc.contributor.authorGlinz, Dominik
dc.contributor.authorGodycki-ćwirko, Maciek
dc.contributor.authorGoossens, Hermann
dc.contributor.authorHolmes, Jane
dc.contributor.authorIeven, Margareta
dc.contributor.authorDe Jong, Menno
dc.contributor.authorLindbaek, Morten
dc.contributor.authorLittle, Paul
dc.contributor.authorMartinón Torres, Federico
dc.contributor.authorMoragas, Ana
dc.contributor.authorPauer, József
dc.contributor.authorPfeiferová, Markéta
dc.contributor.authorRadzeviciene-Jurgute, Ruta
dc.contributor.authorSundvall, Pär-Daniel
dc.contributor.authorTorres, Antoni
dc.contributor.authorTouboul, Pia
dc.contributor.authorVarthalis, Dionyssios
dc.contributor.authorVerheij, Theo
dc.contributor.authorButler, Christopher C.
dc.date.accessioned2020-05-08T17:54:54Z
dc.date.available2020-05-08T17:54:54Z
dc.date.issued2018
dc.description.abstractEffective management of seasonal and pandemic influenza is a high priority internationally. Guidelines in many countries recommend antiviral treatment for older people and individuals with comorbidity at increased risk of complications. However, antivirals are not often prescribed in primary care in Europe, partly because its clinical and cost effectiveness has been insufficiently demonstrated by non-industry funded and pragmatic studiesgl
dc.description.peerreviewedSIgl
dc.description.sponsorshipIn addition to the authors, we would like to acknowledge the contribution of the other members of the 21 ALIC4E co-ordinating centres: Bohumil Seifert, Lars Bjerrum, Mike Moore, Christos Lionis, Katalin Bezzegh, Tom Fahey, Florian Nicula, Carl Llor, Heiner Bucher, Sabine de Weirdt, Jane Barnett, Nicola Blakey, Pascale Bruno, Christine Pintaric, Bernadett Kovács, Réka Pauer, Dovile Narvilaite, Nicolay Jonassen Harbin, Anna Gryko, Basia Pytel, Ania Kowalczyk, Anca Balan, Monica Groza, Patricia Fernandez-Vandellos, Carmen Rodriguez-tenreiro Sanchez, Rosa Morros, Helena Pera, Anna Garcia Sangenis, Sofia Sundvall, Filothei Voltyraki, Irene Vasilaki, Antonios Bertsias and Ioanna Tsiligianni. We also acknowledge and thank the hard work and dedication of all the networks recruitment teams, practices and local laboratories. The authors would like to acknowledge the contribution of the Trial Steering Committee members, namely Patrick Bindels, Gordon Taylor, Åke Örtqvist and Keith Shankland (patient/public representative) and the Independent Data Monitoring Committee members Deborah Ashby, Sonia Saxena and Simon Gates. Also all the members of the Patient and Public Involvement group who contributed to the study design and development. The authors would also like to acknowledge the other members of the collaborative PREPARE work packages, in particular: Nina Gobat and Micaela Gal (WP1); Mandy Kuijstermans, Pieter Moons and Veronique Nussenblatt (WP7) and Frank Leus, Joost Schotsman and Susan van Hemert (WP8). Finally, we acknowledge the help and support from the Nuffield Department of Primary Care Health Sciences and Primary Care Clinical Trials Unit, University of Oxford in particular Sonya Beecher and Julie Allen for their respective administrative and trial management supportgl
dc.identifier.citationBongard E, van der Velden AW, Cook J, et al. Antivirals for influenzaLike Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4 E): the ALIC4 E protocol. BMJ Open 2018;8:e021032. doi:10.1136/ bmjopen-2017-021032gl
dc.identifier.doi10.1136/bmjopen-2017-021032
dc.identifier.issn2044-6055
dc.identifier.urihttp://hdl.handle.net/10347/22175
dc.language.isoenggl
dc.publisherBMJgl
dc.relation.publisherversionhttps://doi.org/10.1136/bmjopen-2017-021032gl
dc.rights© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/gl
dc.rights.accessRightsopen accessgl
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectPandemic influenzagl
dc.subjectAntiviralsgl
dc.subjectEuropegl
dc.subjectALIC4 E protocolgl
dc.subjectInfluenzagl
dc.subjectRetroviralgl
dc.titleAntivirals for influenza-like illness? a randomised controlled trial of clinical and cost effectiveness in primary carE (ALIC4 E): the ALIC4 E protocolgl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication1edfc6d6-58bb-425b-a52a-d2b495d0bb3d
relation.isAuthorOfPublication.latestForDiscovery1edfc6d6-58bb-425b-a52a-d2b495d0bb3d

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2018_bmjopen_bougard_antivirals.pdf
Size:
723.09 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia e Pediatría